Logo

Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation #ASCO2019

Share this
Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation #ASCO2019

Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation #ASCO2019

Shots:

  • The P-II GEOMETRY mono-1 study results involves assessing of Capmatinib (400mg- bid) in 97 treatment-naive & prior treated patients with LA/metastatic NSCLC harboring a MET exon-14 skipping mutation
  • The P-II GEOMETRY mono-1 study results:  ORR based on BIRC assessment / RECIST v1.1 (68% & 41%); DOR (11.14 mos. & 9.72 mos.)- 54% patients showed intracranial activity- presented at ASCO 2019
  • Capmatinib (INC280) is an oral & selective MET inhibitor- licensed by Novartis from Incyte Corporation in 2009 and has received FDA’s BT designation for m-NSCLC with MET exon-14 skipping mutation. Additionally- Novartis presents data of canakinumab (ACZ885) as monothx. in P-III CANOPY study for mid- to late-stage NSCLC

Ref: Novartis | Image: Creative Concept Design

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions